Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech startups are built on venture capital. Track funding rounds ...
2024年11月21日 · With the funding of two startups this week, OrbiMed has passed Alexandria Venture Investments to become the third most active biotech investor since 2022, according to BioPharma Dive data.
Drugmakers are racing to find the next Wegovy. These obesity …
2024年10月10日 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
The biopharma industry outlook on 2024: Guarded optimism for a …
2024年1月16日 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs …
Biotech M&A has plateaued. Track the deals that are happening …
Methodology. For this database, BioPharma Dive looked only at companies developing human medicines. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company — not for product licensings, options to acquire or for partial equity stakes.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
2024年9月27日 · The clearance is expected to further boost sales of Dupixent, which is a key source of revenue for both Sanofi and Regeneron. Since first reaching the U.S. market in 2017 as a treatment for eczema, Dupixent has now been cleared for six other diseases.
Drug patents protect pharma profits. Track when they’ll expire.
2024年5月8日 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Incyte sinks on setback for drugs acquired in $750M buyout
2024年11月19日 · Incyte has already completed enrollment in other proof-of-concept studies of INCB000262 in atopic dermatitis and inducible urticaria. Data from those trials will guide future development of the drug as well as “back-up molecules,” the company said.
Zepbound, Mounjaro back in supply as Lilly resolves shortage
2024年8月5日 · Dive Insight: Lilly has been pouring money into expanding its manufacturing capacity for tirzepatide by opening production at more of its existing facilities, buying factories and building new ones.Still, it hasn’t been able to make tirzepatide fast enough, as demand for the drug and Novo Nordisk’s rival medicines Ozempic and Wegovy soared.
Pfizer to pull sickle cell drug from market, shut down trials
2024年9月26日 · Dive Insight: The withdrawal will remove one of the few treatment options for the millions of people around the world living with sickle cell disease, which causes severe pain and can lead to organ damage, stroke and death.. Oxbryta, a once-a-day tablet, was designed to reduce “sickling,” the warping of red blood cells that leaves them unable to move easily …